This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
This conversation focuses on ways the new MASLD Nomenclature can improve the ways providers explain MASH to patients.
This conversation on the new MASLD nomenclature rollout has two major elements: discussing the role of Allied Health Providers and looking more broadly at the ongoing rollout process.
In this discussion, Jeff Lazarus, who oversaw the global Delphi process that led to the final new MASLD nomenclature, describe how a Delphi process works and some of its strengths and weaknesses here.
In this discussion, Maru Rinella, who co-led the new MASLD nomenclature process, and Jeff Lazarus, who oversaw a large Delphi process that led to the final result, describe how the process came to be.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
In this March, 2023 conversation, Jeff McIntyre from Global Liver Institute talks with Louise Campbell and Roger Green about key upcomoing regulatory events, including an ICER review of resmetirom and obeticholic acid and an FDA workshop on NITs.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to describe their priority MASH programs for 2024.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the role that MASLD patient advocates and others are likely to play in MASH drug access decisions, along with education and informational processes.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the challenges in patient access and education that will follow the first MASH drug approval. expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss their expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Leading MASLD patient advocates Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and Milan Mishkevikj of the European Liver Patients Association join Louise Campbell and Roger Green to share their vision of changes in the MASH world in 2024 along with each organization’s hopes, concerns and plans. The discussion covers the advocates’ hopes and concerns for the year as well as the programs and efforts each considers top priority.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group examines the explosion of telemarketer-driven consumer advertising for GLP-1 agents as anti-obesity medicines and asks what impact this might have on diagnosis, treatment and monitoring of MASH in the US.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group explores the goal of provider and patient liver education, key goals for liver awareness and the potential for direct-to-consumer advertising of GLP-1s for weight loss to garble the “liver awareness” message.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes how VCTE can serve as a behavioral monitor, Roger Green reviews some changes in the podcast this year and the group begins to discuss why “liver awareness” should become an important concept.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes her recent efforts in enhancing liver health awareness and education, focusing on the launch of the user-friendly website MyLife365.me. Also, she shares lessons about patient communication and creating liver awareness.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Jörn Schattenberg describes the challenges, opportunities and experiences that he has found in assuming Department leadership at the University of the Saarlandes.
The first episode of Season 5 of Surfing the MASH Tsunami starts with a brief discussion of what the co-hosts have worked on for the last two months and proceeds to consider the impact on patient treatment of having a MASH drug approved in the US market, particularly in today’s direct-to-consumer weight loss advertising.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Ukraine Public Health Executive Tatiana Deshko, Mike Betel of the Fatty Liver Alliance and co-host Roger Green.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Novo Nordisk International Medical Vice President Michelle Long, along with co-hosts Louise Campbell and Roger Green.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with biotech entrepreneur Rachel Zayas, Founder and CEO of AGED Diagnostics, along with co-hosts Louise Campbell and Roger Green.
